The ADGRG6+ group exhibited higher scores in the P53 pathway, G2/M checkpoint, TGF-β signaling, PI3K-AKT signaling, and oxidative phosphorylation pathways (Figure 6A), corroborating our previous analysis of the TCGA PAAD dataset (Figures 4C, D). This evidence concerns the gene ADGRG6 and pancreatic adenocarcinoma.